A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Public ClinicalTrials.gov record NCT04170283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study. Participants continued receiving zanubrutinib if they were still benefiting from it, or they might have taken part in long-term follow-up after treatment. Information collected in this study will help health authorities better understand the long-term effects of zanubrutinib.
Study identification
- NCT ID
- NCT04170283
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 955 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 16, 2020 (Actual)
- Primary completion
- Dec 31, 2026 (Estimated)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- Aug 28, 2026
2020 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 18
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Md Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Carti Cancer Center | Little Rock | Arkansas | 72205 | — |
| Rocky Mountain Cancer Centers Centennial | Centennial | Colorado | 80112 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Florida Cancer Specialists Fort Myers | Fort Myers | Florida | 33916 | — |
| Scri Florida Cancer Specialists North | St. Petersburg | Florida | 33705 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Forrest General Hospital Cancer Center | Hattiesburg | Mississippi | 39401 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Summit Medical Group | Florham Park | New Jersey | 07932 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Optum Medical Care, Pc. | Westbury | New York | 11590 | — |
| Duke University Hospital | Durham | North Carolina | 27705 | — |
| Oncology Associates of Oregon Willamette Valley Cancer Center | Eugene | Oregon | 97401 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Scri Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology | Nashville | Tennessee | 37205 | — |
| Texas Oncology Fort Worth Cancer Center | Fort Worth | Texas | 76104-2150 | — |
| The University of Texas Md Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| Texas Oncology San Antonio Medical Center Usor | San Antonio | Texas | 78240 | — |
| Oncology and Hematology Associates of Southwest Virginia, Inc | Roanoke | Virginia | 24014 | — |
| University of Washington Seattle Cancer Alliance | Seattle | Washington | 98185 | — |
| Medical Oncology Associates | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 127 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04170283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04170283 live on ClinicalTrials.gov.